Table 9.
Associations between GLO1 genotype and breast cancer
| AA | AE | EE | AA and AE | |
| All | ||||
| Cases, n (%) | 119 (21.8) | 261 (47.7) | 167 (30.5) | 428 (78.2) |
| Controls, n (%) | 317 (58.3) | 159 (29.2) | 68 (12.5) | 227 (41.7) |
| OR (95% CI)a | 1.0 | 4.32 (3.20–5.87) | 6.52 (4.51–9.40)b | 4.94 (3.75–6.50) |
| Menopausal status at diagnosis | ||||
| Premenopausal | ||||
| Cases, n (%) | 39 (20.9) | 84 (44.9) | 64 (34.2) | 148 (79.1) |
| Controls, n (%) | 104 (45.2) | 88 (38.3) | 38 (16.5) | 126 (54.8) |
| OR (95% CI)a | 1.0 | 2.50 (1.51–4.18) | 4.46 (2.50–7.98)b | 3.12 (1.96–4.94) |
| Postmenopausal | ||||
| Cases, n (%) | 80 (22.2) | 177 (49.2) | 103 (28.6) | 280 (77.8) |
| Controls, n (%) | 213 (67.8) | 71 (22.6) | 30 (9.6) | 101 (32.2) |
| OR (95% CI)a | 1.0 | 6.54 (4.38–9.76) | 9.11(5.48–15.05)b | 7.35 (5.14–10.53) |
aAdjusted for age, age at menarche, age at FFTP, number of full term pregnancies, first-degree family history of breast cancer, history of benign breast disease, use of oral contraceptives, WHR, alcohol consumption, smoking habits, level of education and postmenopausal use of estrogen. bP for trend: all, 0.01; premenopausal, 0.03; postmenopausal, 0.01.